MedTech Ditches Legacy Tools for AI-Powered Development Platforms

CAMPBELL, Calif. – May 14, 2026 – A significant shift is accelerating across the medical technology landscape as innovators abandon cumbersome, siloed software for unified, AI-driven platforms. This trend was cast into sharp relief as Enlil, Inc., an AI-powered traceability platform, announced a record-breaking first quarter for 2026, signing eight new MedTech customers in just three months.

The cohort of new clients, which includes trailblazers in organ perfusion, surgical robotics, and AI-driven imaging, signals a clear industry-wide move away from legacy quality management (QMS) and product lifecycle management (PLM) systems. Companies are migrating from established players like Greenlight Guru and PTC Arena, seeking solutions that match the speed and complexity of modern medical device development. The rapid onboarding of these new customers, some going live in a matter of weeks, underscores the urgency for a new generation of development tools.

"Today's MedTech teams move faster than the legacy systems holding them back, and that gap is where the industry's hidden costs live," said Nader Fathi, CEO of Enlil. "Eight new customers in 90 days, replacing legacy systems with rapid go-lives, reflects what's possible when teams get a platform built for the way they truly work."

The Crumbling Silos of MedTech Development

For years, medical device companies have navigated a fragmented digital ecosystem. Critical information for product development—requirements, design controls, risk analysis, manufacturing data, and quality events—has been stored in separate, often incompatible, systems. This creates data silos that impede collaboration, slow down innovation, and introduce significant compliance risks.

Industry analysis reveals that these legacy systems are often burdened with technical debt, making them difficult to upgrade and inflexible to the evolving needs of a fast-paced startup. Teams are frequently forced to adapt their workflows to the rigid structures of their software, rather than the other way around. This inefficiency is more than just a nuisance; it can delay the delivery of life-saving technologies and increase the likelihood of costly errors and audit failures. In a sector where end-to-end traceability is not just a best practice but a regulatory mandate under standards like FDA 21 CFR Part 820 and ISO 13485, a lack of integration between quality and product data is a critical vulnerability.

The move towards platform consolidation is a direct response to these challenges. Innovators are demanding a single source of truth that provides a holistic view of the product lifecycle, from initial concept through to post-market surveillance.

A New Blueprint for Innovation

Enlil's recent success illustrates the appeal of this new paradigm. The Campbell-based company offers a cloud-native platform that unifies QMS, PLM, risk management, procurement, and manufacturing data into a single, integrated system. This approach is designed from the ground up with an "AI-first" architecture, a key differentiator from competitors who may be retrofitting AI capabilities onto older frameworks.

New customers consistently cited five key themes for making the switch. The platform's flexibility allows companies to build custom workflows that mirror their actual processes. Its integrated solution eliminates the need for multiple, disconnected tools. Furthermore, its ability to provide private AI that can reason across a complete dataset, rather than fragmented inputs, offers a significant advantage. Finally, seamless integrations with essential engineering tools like SolidWorks and Onshape prevent the downstream change management headaches that plague disconnected systems.

At the heart of the platform is "Ask Lily," a proprietary AI capability that functions like a cross-departmental expert. This private large language model can surface gaps in documentation, identify potential risks, and synthesize information across the entire development lifecycle, helping teams ensure regulatory readiness. The entire system operates securely within AWS Bedrock, an environment designed to meet the stringent security and compliance demands of the regulated medical device industry.

From Lab to Life: Accelerating Critical Devices

The impact of this technological shift is most evident in the companies it empowers. The new customer list includes firms tackling some of healthcare's most pressing challenges.

iSono Health, for example, is revolutionizing breast cancer screening with the world's first wearable, automated 3D ultrasound platform, ATUSA. The technology, which recently received FDA clearance, aims to improve detection for women with dense breast tissue and make high-quality imaging more accessible. "To scale something this innovative and ambitious without compromising on quality or regulatory rigor, you need infrastructure that matches our rigor," stated Neda Razavi, CEO & Chairwoman of iSono Health. "Enlil does! giving us one connected foundation for traceability, quality, and change management."

Another new client, Vascular Perfusion Solutions (VPS), is advancing organ transplantation with its VP.S ENCORE® device, which uses novel technology for prolonged organ preservation. "We needed a platform we could shape for our processes, not the other way around, and a partner who understood what it means to support a lean, fast-moving MedTech company," said Dr. Rafael Veraza, CEO of Vascular Perfusion Solutions. "Enlil delivered on both, and we were implemented faster than we thought possible."

For these companies, speed is not just a business metric; it directly correlates to patient impact. An integrated platform that streamlines compliance and accelerates development cycles means that critical innovations can reach clinics and patients sooner. Trey Bobo, Chief Operating Officer of Verionyx, another new customer, confirmed the smooth transition, noting, "Our rollout of the quality system is complete, and the team is trained... I have found it to be as intuitive and usable as it seemed in the demos."

The AI-First Mandate in a Regulated World

The integration of artificial intelligence is no longer a futuristic concept in MedTech; it is a present-day reality and a growing competitive necessity. The FDA has already authorized over 1,200 AI-enabled medical devices, with a record 235 approvals in 2024 alone, signaling a clear regulatory pathway for such technologies.

However, the effectiveness of AI is entirely dependent on the quality and completeness of the data it can access. This is where unified platforms hold a decisive advantage. By providing AI agents like "Ask Lily" with a comprehensive, contextually linked dataset spanning the entire product lifecycle, they can deliver insights that are simply impossible to generate from siloed information. These AI tools can automate the creation of test protocols, assess the downstream impact of a design change, and continuously monitor for compliance gaps, transforming AI from a potential risk into a powerful compliance accelerator.

Enlil's momentum reflects a fundamental re-evaluation of the digital infrastructure required to build the next generation of medical devices. As technology becomes more complex and regulatory scrutiny intensifies, the ability to manage development with speed, traceability, and intelligence is paramount. The industry's rapid adoption of integrated, AI-native platforms demonstrates that for today's MedTech pioneers, the old way of working is no longer an option.